# A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Source: https://onco.cc/trials/nct04639219/  
OnCo record `nct04639219` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab deruxtecan in melanoma, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations is a phase 2 interventional study registered as NCT04639219 by AstraZeneca, with 102 participants enrolled, started 2020-12-30 and due to reach its primary completion in 2023-01-25. Interventions recorded: Trastuzumab deruxtecan. Conditions listed: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT04639219
- Phase: 2
- Setting: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology
- Sponsor: AstraZeneca
- Enrolled: 102
- Outcomes: Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR): T-DXd 29.4%; Overall Survival (OS): T-DXd 10.9 months

## Sources

- ClinicalTrials.gov NCT04639219: https://clinicaltrials.gov/study/NCT04639219

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study](https://onco.cc/key-papers/paper-nct04639219-lancet-oncol-2024/)

---
JSON: https://onco.cc/api/v1/entities/nct04639219.json